41 results about "Cell transplantation" patented technology

The invention discloses a cerium nano-enzyme composite active material and application thereof in hepatic failure treatment, and belongs to the technical field of nano-materials. The invention combines the functions of miR122 and cerium dioxide nano-enzyme, develops a new stem cell differentiation inducer, namely a cerium nano-enzyme composite active material, and deeply studies the potential mechanism of the nano-enzyme material with catalytic activity in regulating stem cell fate, and the cerium dioxide nano-enzyme can be used for delivering miR122 into stem cells after being modified, so that the stem cell differentiation inducer can be used for inducing stem cell differentiation. The miR122 is highly enriched in cells, so that hepatic differentiation is induced. Meanwhile, the catalytic activity of the cerium dioxide nano-enzyme can regulate the ROS steady state in the cells and protect mitochondria from being damaged by ROS induction, so that the mitochondrial function is maintained, the energy requirement in the differentiation process is met, and the method is of great importance to successful differentiation of the stem cells. In order to solve the problem of activity damage in hepatic cell transplantation, a layer of Ce < 4 + >-polyphenol skeleton is coated on the surface of induced hepatic-like cells (iHLCs), so that the function and activity of the hepatic cells after transplantation are further protected, and the in-vivo treatment effect of the hepatic cells is improved.

The invention discloses a method for inducing fibroblasts to be reprogrammed into mesenchymal matrix-like cells (MLCs) by using small chemical molecules and application of the mesenchymal matrix-like cells (MLCs) in the anti-aging field. The invention discloses a set of specific chemical small molecule composition and an induction scheme thereof, which can be used for efficiently reprogramming fibroblasts from somatic cells into MLCs. Furthermore, the huge potential of the MLCs obtained by the method in anti-aging research is deeply explored, and the effect of the MLCs is proved to be obviously superior to that of umbilical cord mesenchymal stem cells in the aspects of reversing cell aging phenotypes and recovering tissue functions. The invention not only provides a new stem cell source strategy for avoiding the ethical and safety problems of the traditional reprogramming technology, but also lays a solid cell foundation for developing a novel, safe and effective anti-aging therapy based on cell transplantation or secreted factors.

This invention belongs to the field of genetic engineering and cell modification technology, and discloses a method for constructing and applying anti-aging human mesenchymal stem cells (MSCs). The DHX9-overexpressing virus-transfected MSCs constructed in this invention possess stable DHX9 overexpression effects and anti-aging functions. These MSCs do not target a single gene locus, but rather alleviate a series of aging phenotypes and genomic instability issues during the aging process by eliminating R-loops. DHX9-overexpressing MSCs exhibit significant anti-aging activity, as well as strong environmental adaptability and excellent safety characteristics. They can effectively resist harsh in vivo inflammation and the aging microenvironment, while avoiding the tumorigenic risk after cell transplantation. These MSCs with stable anti-aging capabilities can subsequently be used to significantly improve the efficacy of MSC infusion therapy for diseases.

Described herein, inter alia, are compositions and methods of use for administering a population of regulatory T (TREG) cells and / or a population of midbrain dopamine (mDA) cells to the brain of a subject (e.g., treating Parkinson's disease and / or reducing immune responses due to acupuncture wounds during cell transplantation).

The present disclosure provides compositions and methods for cell transplantation therapy based on forced expression of an exogenous HLA-F protein in donor cells to be transplanted into a subject. In some embodiments, the donor cells express an exogenous chimeric HLA-F protein comprising an extracellular region comprising an HLA-F alpha 1 domain, an HLA alpha 2 domain, an HLA-F alpha 3 domain, a linker and a β2m protein.

The invention discloses a stem cell spray preparation. The stem cell spray preparation is prepared from a mesenchymal stem cell suspension, albumin, glutathione, resveratrol, poloxamer 188 and normal saline. According to the stem cell spray preparation, albumin and normal saline are added, colloid osmotic pressure and crystal osmotic pressure of cells are maintained, glutathione, resveratrol and poloxamer 188 are added at the same time, mechanical shear force in the mesenchymal stem cell spray resisting process can be enhanced, apoptotic cells are reduced, and the clinical effect of target cells is improved; the method is beneficial to the transformation of a cell transplantation mode in stem cell treatment, simplifies the operation difficulty of clinical stem cell use, and contributes to the clinical popularization of stem cells.

This invention discloses a co-culture immune isolation device after cell transplantation, belonging to the technical field of cell culture devices. The device includes a culture plate with several first cavities inside and placement slots outside the first cavities. A cover plate is provided above the culture plate, and several second cavities are provided on the cover plate. A sealing ring is provided on the outside of the second cavities, and a liquid inlet mechanism is provided inside the cover plate, connected to the second cavities. This invention uses the above-mentioned co-culture immune isolation device after cell transplantation to achieve co-culture of multiple cells by setting multiple independent first cavities, preventing cell migration or direct contact and avoiding immune rejection. The protective cover and liquid inlet mechanism achieve closed-loop automatic liquid inlet, continuously diffusing signal molecules into the first cavities to maintain co-culture homeostasis and achieve co-culture of multiple cells.

This invention provides transformed cells for the production of transformed replica pigs for xenotransplantation. [Solution] This invention relates to a transformed replica pig from which the heterologous antigens GGTA1, CMAH, iGb3s, β4GalNT2, and β2M genes have been removed from a PERV Envelope C-negative base, and a method for producing the same. The transformed replica pig according to the present invention can overcome hyperacute and antigen-antibody-mediated immune rejection reactions and T-cell-mediated immune rejection reactions without causing the transfer of porcine endogenous retroviruses that occur in xenologous organ transplantation, and can be usefully utilized as a donor animal for interspecies organ and cell transplantation.

The invention belongs to the technical field of gene engineering and cell transformation, and discloses a gene engineering construction method and application of anti-aging human mesenchymal stem cells. The DHX9 overexpression virus transfected MSCs constructed by the invention have a stable DHX9 overexpression effect and an anti-aging function, and the MSCs relieve a series of problems of aging phenotypes and unstable genomes in an aging process by eliminating R-loop instead of aiming at a single gene locus. The DHX9 overexpression MSCs show significant anti-aging activity, also have strong adaptive capacity to environment and excellent safety characteristics, can effectively resist harsh in-vivo inflammation and aging microenvironment, and at the same time avoids tumorigenic risk after cell transplantation. The MSCs with the stable anti-aging capability can be subsequently applied to remarkably improving the treatment effect of MSCs infused into a body for treating diseases.

The application provides a stem cell transplantation bone marrow infusion pump, and belongs to the technical field of stem cell infusion pumps.The stem cell transplantation bone marrow infusion pump comprises a body, a control panel is arranged on the top of the body, a movable clamping frame is slidably connected in the body, a handle is arranged on one side of the body, a base is arranged at the bottom of the body, a piston push rod is arranged at one end of the movable clamping frame, an injection barrel is slidably connected at one end of the piston push rod, a connector is arranged at one end of the injection barrel, and a hose is arranged at one end of the connector.The stem cell transplantation bone marrow infusion pump is provided with a stress detection pipe clamp assembly and an adjustable clamping assembly, so that the infusion pump can be pulled out and disassembled and assembled in a fault mode, the ability to deal with emergencies is improved, the stem cells in the injection barrel are prevented from being affected by external force and overflowing, a physical isolation barrier is formed, the leakage risk caused by collision or accidental touch is effectively reduced, the injection barrel can be quickly clamped and adapted, and the compatibility is improved.

Provided herein are lung forming progenitor cell therapies which do not require pre-conditioning treatments. Administration of the progenitor cells can replace or replenish populations of host-derived patch forming cells to reverse or inhibit fibrosis, promote healing, and improve lung function. Further disclosed herein are methods for monitoring fibrosis, and for determining whether a subject will be receptive to progenitor cell treatments.

The present invention relates to a composition for promoting the osteogenic differentiation efficiency of adipose-derived stem cells. The present invention has revealed that treating Adipose-Derived Stem Cells (ADSCs) from older donors with reduced differentiation efficiency with FGF2 and / or HGF during the early stages of differentiation can restore damaged paracrine function and maximize differentiation efficiency. Therefore, it can be utilized as an in vitro process technology for promoting stem cell differentiation efficiency before or during adipose-derived stem cell transplantation.

The application belongs to the technical field of genetic engineering and cell modification, and discloses a genetic engineering construction method and application of an anti-aging human mesenchymal stem cell. Based on eliminating R-loop formed in the process of cell aging from the source, relieving the adverse effects of genome instability caused by R-loop, the application develops RNH1 overexpression virus transfection MSC aiming at eliminating cell R-loop. The RNH1 overexpression MSC provided by the application exhibits significant anti-aging activity, has strong environmental adaptability and excellent safety characteristics, can effectively resist harsh in-vivo inflammation and aging microenvironment, and avoid the tumorigenic risk after cell transplantation, and the MSCs with stable anti-aging ability can be applied to significantly improve the curative effect of MSCs infusion in-vivo disease treatment.

The present invention relates to a matriptase-2 (MT2) inhibitor, a TMPRSS6 inhibitor, a ferroportin blocker, or a hepcidin enhancer. In particular, the present invention relates to the use of compounds capable of reducing at least one of the following: systemic iron levels, transferrin saturation (Tsat), non-transferrin-bound iron (NTBI), and unstable plasma iron (LPI). This may occur by inhibiting the expression of a target gene, where the target gene may be a transmembrane protease, serine 6 (TMPRSS6). Furthermore, the present invention relates to compositions comprising the above compounds, and methods of using such compounds and / or compositions. Such use may include therapeutic use, for example, to reduce iron overload and prevent iron-related toxicity, before, during, or after chemotherapy pretreatment, stem cell transplantation, and engraftment.

Novel nucleic acid compositions, vectors, modified cells and pharmaceutical compositions are provided that are useful for treating or preventing a relapse of a haematological malignancy after allogeneic stem cell transplantation (allo-SCT) in a HLA-A*0201 positive human subject. Corresponding methods and uses are also provided.

This method for estimating the therapeutic effect of stem cell transplantation comprises: a step (S11) for acquiring a plurality of cell images in which a stem cell group in culture is imaged at a plurality of predetermined time points within a cell culturing period for stem cell transplantation for regenerative medicine purposes; a step (S12) for identifying stem cell regions respectively in the plurality of cell images; a step (S13) for acquiring, on the basis of the identified stem cell regions, a plurality of types of index values associated with the stem cell group with respect to each of the plurality of cell images; and a step (S14) for estimating, before the transplantation of the stem cell group obtained by the cell culturing, the therapeutic effect of the transplantation of the stem cell group on the basis of the acquired plurality of types of index values. The plurality of types of index values acquired in step (S13) include a plurality of types of index values associated with the morphologies of the stem cells.

The invention discloses a combined cell transplantation system for Huntington's disease treatment, a preparation method and application. The invention belongs to the technical field of biomedicine, and aims at solving the problems that when an existing stem cell transplantation technology is used for treating the Huntington's disease (HD), the graft survival rate is low, differentiation uncertainty is high, and integration with a host neural network is difficult. The combined cell transplantation system for treating the Huntington's disease comprises human umbilical cord mesenchymal stromal cells (hUC-MSCs) and striatum organoid (hStrOs), the human umbilical cord mesenchymal stromal cells play a role in immunoregulation and provide endogenous immune microenvironment support, and the human umbilical cord mesenchymal stromal cells play a role in immunoregulation and provide endogenous immune microenvironment support; the striatum organ takes medium spinous projective neurons (MSNs) for expressing DARPP-32 and CTIP-2 as a main body, and undertakes a cell replacement function. The HD cell therapy is promoted to be converted from a traditional single cell replacement mode to an'immune regulation-nerve regeneration 'multi-dimensional functional remodeling mode through cooperation of the HD cell therapy and the Huntington's disease, and a new way is provided for cell therapy of the Huntington's disease.

The utility model relates to the technical field of stem cell transplantation, in particular to a stem cell transplantation device which comprises a syringe, a piston rod is arranged in the syringe, a transplantation needle is mounted at one end of the syringe, a threaded pipe is fixed at one end of the surface of the syringe, a control valve is mounted on the surface of the threaded pipe, and a stem cell is arranged on the control valve. A push-and-pull mechanism is arranged on the surface of the injection cylinder, a supporting piece, a handle, a guide rod and a hanging bolt are arranged in the push-and-pull mechanism, a supporting mechanism is arranged on the outer side of the transplanting needle head and composed of a supporting assembly and an inner threaded ring, and a multi-sealing mechanism is arranged on the surface of the threaded pipe. And a sealing ring, an upper sealing air bag, a lower sealing air bag and an air guide hose are arranged in the multi-sealing mechanism. The stability of the transplanting device in use is improved, the sealing effect of the threaded pipe in use of the transplanting device is improved, push-and-pull work can be completed with one hand, and labor is saved.

The utility model discloses an autologous fat component separation filler, and relates to the technical field of fat filling. Comprising a main body, the main body is composed of a push-injection cylinder and a filling cylinder, the lower inner wall of the push-injection cylinder is fixedly sleeved with a sealing plate, one end, away from the sealing plate, of the push-injection cylinder is rotatably provided with a push-injection knob, the surface of the push-injection knob is sleeved with a lead screw in a penetrating and threaded mode, and a push rod is fixedly installed at the end of the lead screw and slides at the bottom of the sealing plate in a limited mode; a piston head is fixedly installed at the end, away from the lead screw, of the push rod and sleeved with the inner wall of the filling cylinder. The push injection knob is rotated to drive the screw rod in threaded engagement with the push injection knob to move up and down, and in the process, the sliding groove slidably sleeves the surface of the convex block to play a limiting role, so that the piston head makes piston motion on the inner wall of the filling cylinder, constant-speed separation and filling of autologous fat are achieved, and the filling speed can be accurately controlled; therefore, the survival rate of fat cell transplantation is improved.

The invention provides a composition containing neural stem cells, which comprises the following components in parts by mass: 15-20 parts of neural stem cells which are subjected to hypoxia pretreatment and chemical protective agent treatment; 30 to 40 parts of a collagen-sodium alginate composite carrier; 5-8 parts of compound active factors, wherein the compound active factors comprise endostatin, recombinant human epidermal growth factors and superoxide dismutase; and 100 parts of cell protection liquid, wherein the cell protection liquid comprises thioredoxin and nicotinamide. The composition is used for preparing a medicine for treating retina degenerative diseases, and the medicine is an intravitreal injection preparation. The composition synchronously overcomes the three technical bottlenecks of low cell transplantation survival rate, out-of-control differentiation direction and neural network reconstruction disorder through neural stem cell hypoxia pretreatment, active factor compound network, collagen-sodium alginate carrier mechanical adaptation and multi-channel synergistic intervention of a redox protection system.

Provided herein is a lung-forming progenitor cell therapy that does not require preconditioning treatment. Administration of the progenitor cells can replace or replenish a population of host-derived patch-forming cells to reverse or suppress fibrosis, promote healing, and improve lung function. Also disclosed herein are methods for monitoring fibrosis and determining whether a subject is susceptible to progenitor cell therapy.

The invention provides methods of irradiating PSC-derived islet-like clusters with low-dose X- ray; irradiated PSC-derived islet-like clusters for cell therapy with improved safety profile and / or reduced proliferative off-target cells; and irradiated PSC-derived islet-like clusters and cell transplants for use in treatment.

The present disclosure discloses a technical method for treating vitiligo through hair follicle melanocyte stem cell transplantation. The technical method comprises the following steps: extraction of hair follicles; separation of hair follicles; in-vitro culture of hair follicle melanocyte stem cells; inactivation of hair follicles; and transplantation of hair follicle melanocyte stem cells. According to the present disclosure, outer root sheaths of hair follicles containing the hair follicle melanocyte stem cells are obtained through a precise extraction and separation method. Through in-vitro separation and culture and inactivation of hair follicles, a situation that vitiligo only turns black without hairs after surgery is achieved. Through precise transplantation, the original color of the punctate multi-hair follicle orifice can be restored, thereby achieving the purpose of rapidly removing white patches.

The invention discloses a cardiac function preparation as well as a preparation method and application thereof, and belongs to the technical field of preparation of cardiac muscle repair stem cell preparations. Performing mixed culture on endothelial progenitor cells and a heart extracellular matrix to obtain composite cell spheres; carrying out mixed culture on the myocardial-like cell sheet and the composite cell spheres, and after the composite cell spheres are uniformly distributed on the cell sheet and are in a fusion trend, cutting the composite cell spheres into pieces to obtain cell sheet-cell sphere composite particles; and uniformly mixing the composite particles with a poloxamer P407 solution to obtain the heart function preparation. Wherein the endothelial progenitor cells are combined with the cardiac extracellular matrix for use, so that angiogenesis in cardiac tissues can be effectively promoted, cell spheres and myocardial-like cell patches are compounded and cut into pieces, and the pieces can be better adhered to myocardial infarction positions for targeted repair. Experiments prove that the cardiac function preparation can effectively promote angiogenesis of cardiac tissue and myocardial infarction tissue repair, and the problem that the repair function is limited due to the fact that the number of survival cells is insufficient after cell transplantation in a stem cell therapy is solved.

The object of the present invention is to provide a decellularized graft which is easily manufactured. The problem can be solved by a decellularized cell aggregate, wherein a cultured cell aggregate is decellularized, and surface pores with pore diameter of 5µm or more are 3 to 45 per 11088µm2 of aggregate surface, and / or a decellularized cell aggregate, wherein a cultured cell spheroid is decellularized, and lamin of 10pg / mg or more is contained with respect to the decellularized cell aggregate.

The invention belongs to the technical field of gene engineering and cell transformation, and discloses a gene engineering construction method and application of anti-aging human mesenchymal stem cells. On the basis that R-loop formed in the cell aging process is eliminated from the source, the adverse effect of genome instability caused by the R-loop is relieved, and RNH1 overexpression virus transfection MSC for cell R-loop elimination is developed. The RNH1 overexpressed MSCs provided by the invention show remarkable anti-aging activity, also have strong adaptive capacity to environment and excellent safety characteristics, can effectively resist harsh in-vivo inflammation and aging microenvironment, avoids tumorigenic risk after cell transplantation, and has good application prospects. The MSCs with stable anti-aging capability can be subsequently applied to remarkably improving the treatment effect of the MSCs infused into a body for treating diseases.

The present invention provides clinical evidence for a method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring myeloablative conditioning.

Disclosed in the present invention is an optimized cell transplant. The optimized cell transplant is formed by performing gene induction and modification on a mesenchymal stem cell in the form of a small molecule and protein composition. The expression levels of CD200 gene, Galectin-9 gene and VISTA gene can be increased synchronously after cell culture. Vector virus infection and plasmid transfection are not required in the cell preparation process, so that high biological safety and great clinical application value of cells are achieved. The optimized cell transplant is suitable for the technical field of mesenchymal stem cells applied to cell transplantation therapy, and the therapeutic effect of the optimized cell transplant is more excellent than that of the non-modified mesenchymal stem cell.

In various embodiments, the present disclosure provides non-human animals comprising human immune cell transplantation and / or a functional human immune system. In various embodiments, the disclosure also provides methods of making the non-human animal. In various embodiments, the disclosure also provides methods of determining the immunogenicity of an antigen or an immunogenic fragment thereof or an antigen therapy and / or identifying an agent that modulates an immune response.

The present invention relates to a process for preparation of compositions comprising human umbilical cord blood plasma and a designed specific culture medium to grow these cells in specific conditions.The compositions of the present invention are rich in regenerative factors derived from mesenchymal stem cells and together with other designed culture medium factors and processes, are useful in tissue regeneration processes and for preservation, conservation and expansion of mesenchymal stem cells. In fact, the present invention allows a better therapeutic option compared to traditional cell transplantation, as it can benefit from the local tissue response to the secreted molecules without the difficulties and complications associated to the engraftment of the allo- or xeno-transplanted mesenchymal stem cells.Therefore, the present invention is in the field of cell-based therapies for skeletal disorders, such as joint disorders, disorders of connective tissue, bone diseases, osteoporosis, and other damaged tissues, and for modulating the inflammatory process related to tissue regeneration as well.